Given the recent approval of a TCR-based therapy, industry stakeholders have initiated several R&D efforts focused on evaluating the potential of such therapy candidates against various disease indications
Roots Analysis has announced the addition of “Global TCR-based Therapy Market (2nd Edition), 2022-2035” report to its list of offerings.
Growing burden and unaddressed complex treatment needs of cancer patients have paved the way for more effective, safe and versatile alternatives, such as TCR therapies. Driven by Kimmtrak® approval, promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is anticipated to witness significant growth in the mid to long-term
Key Market Insights
Over 190 TCR-based therapies are currently approved / under development
Close to 45% of the aforementioned candidates are being evaluated in clinical trials (phase I and above), while 30% of them are in preclinical stage of development. More than 90% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, NY-ESO-1 and MAGE have emerged as the most popular target antigens.
More than 7,000 patients have been enrolled in nearly 110 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% are active and still recruiting patients, while close to 26% have already been completed.
Partnership activity within this domain has grown at a CAGR of 27%, between 2015 and 2021
More than 70 agreements have been inked in the last 5 years. Majority of partnership deals signed within this domain were R&D agreements (26%), licensing agreements (21%), and product development and commercialization agreements (16%).
Over 11.2 USD billion has been invested by both private and public investors in this domain, since 2007
Specifically, in 2020 and 2021, industry players raised over USD 2.7 billion. In addition, majority (39%) of the companies primarily received funding through venture capital rounds. Further, around 70% of the total funding instances were reported by players headquartered in the US.
More than 70 patents have been filed / published related to the TCR-based therapies
Close to 85% of the filed / published patents were patent applications, while around 15% were granted patents and others. Of the total granted applications, close to 45% were filed in North America and Europe.
The market is anticipated to grow at a CAGR of 51%, during the period 2022-2035
In 2035, close to 60% of the market revenues are expected to be generated from sales of therapeutics intended for Nasopharyngeal Carcinoma and Multiple Myeloma. Further, therapies targeting for NY-ESO-1 are expected to occupy a larger share (~50%) of the overall market in 2035.
Key Questions Answered
• What is the growth rate of TCR-based therapy market?
• Which region has the highest growth rate in the TCR-based Therapies market?
• Who are the leading industry and non-industry players in this market?
• How many players are developing TCR-based Therapies?
• Which target indication covers the largest TCR-based therapy market share?
• What is the partnership and collaboration trend in the TCR-based therapy domain?
• What is the current IP landscape of TCR-based therapies market?
The financial opportunity within the TCR-based therapies market has been analyzed across the following segments:
Target Indication(s)
• Nasopharyngeal Carcinoma
• Multiple Myeloma
• Head and Neck Carcinoma
• Sarcoma, Melanoma
• Acute Myeloid Leukemia
• Lung Cancer
• Ovarian Cancer
• Merkel Cell Cancer
Target Antigen
• NY-ESO-1
• EBV
• gp100
• Others
Key Geographical Regions
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and North Africa
• Rest of the World
The report features inputs from eminent industry stakeholders, according to whom, T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:
• Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
• Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
• Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
• Miguel Forte (Former Chief Operating Officer, TxCell)
The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about TCR-based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to TCR-based therapies and manufacturing capabilities of the players.
• Adaptimmune Therapeutics
• Alaunos Therapeutics
• Bristol Myers Squibb
• Cellular Biomedicine Group
• Gilead Sciences
• GlaxoSmithKline
• Immatics
• Immunocore
• Lion TCR
• Takara Bio
• Zelluna Immunotherapy